Although the antibodies targeting PD-1/PD-L1 pathways such as pembrolizumab, nivolumab and atezolizumab can achieve long-lasting tumor regression, the low response rate still remains a major obstacle for treating melanoma patients2,6,13. Here, PDCD1 is linked to neoplasm.